These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 38741006)

  • 1. CRISPR/Cas9 genome editing of CCR5 combined with C46 HIV-1 fusion inhibitor for cellular resistant to R5 and X4 tropic HIV-1.
    Khamaikawin W; Saisawang C; Tassaneetrithep B; Bhukhai K; Phanthong P; Borwornpinyo S; Phuphuakrat A; Pasomsub E; Chaisavaneeyakorn S; Anurathapan U; Apiwattanakul N; Hongeng S
    Sci Rep; 2024 May; 14(1):10852. PubMed ID: 38741006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneous Knockout of CXCR4 and CCR5 Genes in CD4+ T Cells via CRISPR/Cas9 Confers Resistance to Both X4- and R5-Tropic Human Immunodeficiency Virus Type 1 Infection.
    Yu S; Yao Y; Xiao H; Li J; Liu Q; Yang Y; Adah D; Lu J; Zhao S; Qin L; Chen X
    Hum Gene Ther; 2018 Jan; 29(1):51-67. PubMed ID: 28599597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A simultaneous knockout knockin genome editing strategy in HSPCs potently inhibits CCR5- and CXCR4-tropic HIV-1 infection.
    Dudek AM; Feist WN; Sasu EJ; Luna SE; Ben-Efraim K; Bak RO; Cepika AM; Porteus MH
    Cell Stem Cell; 2024 Apr; 31(4):499-518.e6. PubMed ID: 38579682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The CRISPR-Cas9 induced CCR5 Δ32 mutation as a potent gene therapy methodology for resistance to HIV-1 variant: a review.
    Saifullah M; Laghzaoui O; Ozyahyalar H; Irfan A
    Eur Rev Med Pharmacol Sci; 2024 Mar; 28(6):2430-2463. PubMed ID: 38567606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CRISPR/Cas9-Mediated CCR5 Ablation in Human Hematopoietic Stem/Progenitor Cells Confers HIV-1 Resistance In Vivo.
    Xu L; Yang H; Gao Y; Chen Z; Xie L; Liu Y; Liu Y; Wang X; Li H; Lai W; He Y; Yao A; Ma L; Shao Y; Zhang B; Wang C; Chen H; Deng H
    Mol Ther; 2017 Aug; 25(8):1782-1789. PubMed ID: 28527722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of HIV-1 infection of primary CD4+ T-cells by gene editing of CCR5 using adenovirus-delivered CRISPR/Cas9.
    Li C; Guan X; Du T; Jin W; Wu B; Liu Y; Wang P; Hu B; Griffin GE; Shattock RJ; Hu Q
    J Gen Virol; 2015 Aug; 96(8):2381-2393. PubMed ID: 25854553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CCR5 editing by Staphylococcus aureus Cas9 in human primary CD4
    Xiao Q; Chen S; Wang Q; Liu Z; Liu S; Deng H; Hou W; Wu D; Xiong Y; Li J; Guo D
    Retrovirology; 2019 Jun; 16(1):15. PubMed ID: 31186067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiretrovirals to CCR5 CRISPR/Cas9 gene editing - A paradigm shift chasing an HIV cure.
    Khan A; Paneerselvam N; Lawson BR
    Clin Immunol; 2023 Oct; 255():109741. PubMed ID: 37611838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Closing the Door with CRISPR: Genome Editing of CCR5 and CXCR4 as a Potential Curative Solution for HIV.
    Freen-van Heeren JJ
    BioTech (Basel); 2022 Jul; 11(3):. PubMed ID: 35892930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycosylphosphatidylinositol-Anchored Anti-HIV scFv Efficiently Protects CD4 T Cells from HIV-1 Infection and Deletion in hu-PBL Mice.
    Ye C; Wang W; Cheng L; Li G; Wen M; Wang Q; Zhang Q; Li D; Zhou P; Su L
    J Virol; 2017 Feb; 91(3):. PubMed ID: 27881659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biallelic, Selectable, Knock-in Targeting of CCR5
    Scheller SH; Rashad Y; Saleh FM; Willingham KA; Reilich A; Lin D; Izadpanah R; Alt EU; Braun SE
    Front Immunol; 2022; 13():821190. PubMed ID: 35386712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased Efficiency for Biallelic Mutations of the
    Lin D; Scheller SH; Robinson MM; Izadpanah R; Alt EU; Braun SE
    CRISPR J; 2021 Feb; 4(1):92-103. PubMed ID: 33616448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inducing CCR5Δ32/Δ32 Homozygotes in the Human Jurkat CD4+ Cell Line and Primary CD4+ Cells by CRISPR-Cas9 Genome-Editing Technology.
    Qi C; Li D; Jiang X; Jia X; Lu L; Wang Y; Sun J; Shao Y; Wei M
    Mol Ther Nucleic Acids; 2018 Sep; 12():267-274. PubMed ID: 30195765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Membrane-Anchored Short-Peptide Fusion Inhibitor Fully Protects Target Cells from Infections of Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.
    Tang X; Jin H; Chen Y; Li L; Zhu Y; Chong H; He Y
    J Virol; 2019 Nov; 93(22):. PubMed ID: 31462566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CRISPR-Edited Stem Cells in a Patient with HIV and Acute Lymphocytic Leukemia.
    Xu L; Wang J; Liu Y; Xie L; Su B; Mou D; Wang L; Liu T; Wang X; Zhang B; Zhao L; Hu L; Ning H; Zhang Y; Deng K; Liu L; Lu X; Zhang T; Xu J; Li C; Wu H; Deng H; Chen H
    N Engl J Med; 2019 Sep; 381(13):1240-1247. PubMed ID: 31509667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis and dissociation of anti-HIV effects of shRNA to CCR5 and the fusion inhibitor C46.
    Ledger S; Howe A; Turville S; Aggarwal A; Savkovic B; Ong A; Wolstein O; Boyd M; Millington M; Gorry PR; Murray JM; Symonds G
    J Gene Med; 2018 Feb; 20(2-3):e3006. PubMed ID: 29552747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations That Increase the Stability of the Postfusion gp41 Conformation of the HIV-1 Envelope Glycoprotein Are Selected by both an X4 and R5 HIV-1 Virus To Escape Fusion Inhibitors Corresponding to Heptad Repeat 1 of gp41, but the gp120 Adaptive Mutations Differ between the Two Viruses.
    Zhuang M; Vassell R; Yuan C; Keller PW; Ling H; Wang W; Weiss CD
    J Virol; 2019 Jun; 93(11):. PubMed ID: 30894471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro.
    Svicher V; Balestra E; Cento V; Sarmati L; Dori L; Vandenbroucke I; D'Arrigo R; Buonomini AR; Van Marck H; Surdo M; Saccomandi P; Mostmans W; Aerssens J; Aquaro S; Stuyver LJ; Andreoni M; Ceccherini-Silberstein F; Perno CF
    Antiviral Res; 2011 Apr; 90(1):42-53. PubMed ID: 21349294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CCR5 as a natural and modulated target for inhibition of HIV.
    Burke BP; Boyd MP; Impey H; Breton LR; Bartlett JS; Symonds GP; Hütter G
    Viruses; 2013 Dec; 6(1):54-68. PubMed ID: 24381033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination gene therapy for HIV using a conditional suicidal gene with CCR5 knockout.
    Mehmetoglu-Gurbuz T; Yeh R; Garg H; Joshi A
    Virol J; 2021 Jan; 18(1):31. PubMed ID: 33516234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.